Research programme: collagen tolerance immunotherapies - Bone MedicalAlternative Names: BN-007; Joint protection & collagen tolerance programme - Bone Medical
Latest Information Update: 01 Feb 2013
At a glance
- Originator Bone Medical
- Developer Bone Medical; Institute of Bone & Joint Research
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Rheumatoid arthritis
Most Recent Events
- 01 Feb 2013 Preclinical development is ongoing in Australia